GPAT3 is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma. [PDF]
Zhou Y +10 more
europepmc +1 more source
BRAF-activated ARSI suppressed EREG-mediated ferroptosis to promote BRAFV600E (mutant) papillary thyroid carcinoma progression and sorafenib resistance. [PDF]
Chen X +6 more
europepmc +1 more source
Deciphering the role of non-coding RNAs involved in sorafenib resistance. [PDF]
Jing F +6 more
europepmc +1 more source
N6-methyladenosine-modified long non-coding RNA KIF9-AS1 promotes stemness and sorafenib resistance in hepatocellular carcinoma by upregulating SHOX2 expression. [PDF]
Yu Y +7 more
europepmc +1 more source
Retracted: Studying the Role and Molecular Mechanisms of MAP4K3 in Sorafenib Resistance of Hepatocellular Carcinoma. [PDF]
International BR.
europepmc +1 more source
Correction: Epigenetic regulation of DNA repair gene program by Hippo/YAP1-TET1 axis mediates sorafenib resistance in HCC. [PDF]
Mo C +9 more
europepmc +1 more source
Disulfidptosis-related gene expression reflects the prognosis of drug-resistant cancer patients and inhibition of MYH9 reverses sorafenib resistance. [PDF]
Zhang K +6 more
europepmc +1 more source
Epigenetic regulation of DNA repair gene program by Hippo/YAP1-TET1 axis mediates sorafenib resistance in HCC. [PDF]
Mo C +9 more
europepmc +1 more source
Related searches:
Broadening horizons: the role of ferroptosis in cancer
Nature Reviews Clinical Oncology, 2021Xin Chen, Rui Kang, Guido Kroemer
exaly

